MAIA Biotechnology (MAIA) Operating Income (2021 - 2026)

MAIA Biotechnology (MAIA) has reported Operating Income for 6 consecutive years, with -$8.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Income fell 61.0% year-over-year to -$8.3 million in Q2 2026; TTM through Jun 2026 was -$28.9 million, a 46.3% decrease from a year earlier, with the FY2025 full-year figure at -$24.3 million, down 43.12% from the prior year.
• Operating Income was -$8.3 million for Q2 2026 at MAIA Biotechnology, down from -$6.9 million in the prior quarter.
• Over five years, Operating Income peaked at -$3.4 million in Q2 2022 and troughed at -$9.4 million in Q3 2025.
• A 5-year average of -$5.2 million and a median of -$4.8 million in 2023 frame the typical range for Operating Income.
• Across the five-year window, Operating Income tumbled 128.17% in 2022 and increased 21.53% in 2024, its largest moves.
• Over 5 years, Operating Income stood at -$4.2 million in 2022, then plunged by 52.03% to -$6.4 million in 2023, then advanced by 21.53% to -$5.0 million in 2024, then advanced by 13.73% to -$4.3 million in 2025, then slumped by 92.65% to -$8.3 million in 2026.
• The last three Operating Income figures came in at -$8.3 million (Q2 2026), -$6.9 million (Q1 2026), and -$4.3 million (Q4 2025), per Business Quant data.